The NO-VAX Nightmare: Universal Vaccine Developed with Artificial Intelligence Tested on Humans

The University of Cambridge and the startup DIOSynVax have announced the results of the first clinical study on humans of a new vaccine technology that aims to overcome one of the main limitations of current vaccines: the need to be continuously updated to keep up with the evolution of viruses.

The vaccine candidate, developed through computational simulations and machine learning algorithms, was tested on 39 healthy volunteers and demonstrated a favorable safety profile, with no significant side effects. The study represents an important step as it is the first vaccine whose active component was entirely designed using computer simulations before being evaluated in humans.

The goal of the research is to create so-called "universal vaccines," capable of providing extended protection not only against already known variants of a virus but also against related strains that may emerge in the future. Specifically, the trial involved a vaccine aimed at Sarbecoviruses, the subgroup of coronaviruses that includes SARS-CoV-2, responsible for the COVID-19 pandemic, and the virus from the 2003 SARS outbreak.

To design the vaccine, researchers analyzed the entire genetic sequence database of Sarbecoviruses collected from international surveillance programs. Through machine learning techniques, a "super-antigen" was created, a synthetic structure that incorporates the immunological features shared by the entire viral family. The idea is to train the immune system to recognize common elements across numerous related viruses, reducing the impact of mutations that typically make conventional vaccines less effective.

According to results published in the Journal of Infection, the vaccine induced an immune response not only against SARS-CoV-2 and SARS-CoV but also against several coronaviruses found in bats that are considered potential candidates for future spillover events to humans.

The technology could represent a paradigm shift compared to the current approach. Today, vaccines like seasonal flu vaccines or periodic updates to COVID vaccines are developed based on already circulating variants. However, the high mutation rate of viruses can reduce the effectiveness of formulations during the time between development, production, and distribution.

An additional innovative element pertains to the method of administration used during the clinical study. The vaccine was delivered as a DNA vaccine through a needle-free microfluidic jet system. This solution could facilitate large-scale vaccination campaigns and reduce some of the logistical difficulties associated with traditional injections.

The clinical tests were conducted at the facilities of the National Institute for Health and Care Research in Southampton and Cambridge, involving volunteers aged between 18 and 50 years. However, the results obtained represent only the first step in the development pathway. Larger Phase 2 studies will be necessary to verify the vaccine's capacity to generate a robust and lasting immune response in more numerous and diverse populations.

The platform developed by DIOSynVax is not limited to coronaviruses. The company is applying the same approach to vaccine candidates against seasonal and pandemic influenza, hemorrhagic fever viruses like Ebola, and other viral families considered pandemic risks. If future trials confirm the preliminary results, this technology could help transform vaccine development from a reactive model, based on chasing emerging variants, to a preventive approach capable of anticipating pathogen evolution and strengthening preparedness against future pandemics.